Patient Satisfaction With Ravulizumab Treatment for Generalized Myasthenia Gravis (gMG) in the United States (US)
Chelsea Shugars1, Brianna Poole2, Karen Yee3, Jeffrey Yu3, Nicole Betor4, Elizabeth Crevier4, Christopher Scheiner2
1Erlanger Health System, 2University of Tennessee Medical Center, 3Alexion, AstraZeneca Rare Disease, 4Avalere
Objective:
To understand the real-world patient experience with ravulizumab, including health-related quality of life (HR-QoL) and other disease-related impacts, and to determine key drivers of the ravulizumab treatment experience using a patient satisfaction survey.
Background:
Anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG is a rare, chronic, autoimmune disease. Ravulizumab, a terminal complement component 5 inhibitor with maintenance dosing of once every 8 weeks (Q8W), is approved for the treatment of AChR-Ab+ gMG. Here, we present results of a patient satisfaction survey among US adults with gMG receiving ravulizumab.
Design/Methods:
This cross-sectional, web-based survey, conducted from June–August 2025, was developed with input from patients and healthcare professionals. Participants were recruited from patient panels through a recruitment vendor partner and through US patient advisory groups. The survey assessed demographics/clinical characteristics, HR-QoL measures (eg, ability to socialize, function in a career, sleep, manage activities of daily living [ADL]), and treatment satisfaction.
Results:
The analysis included 124 respondents (female: 59%; mean±SD age: 47±13.3yrs; mean±SD Myasthenia Gravis ADL score: 6.5±4.3). Most respondents (73%) had received ravulizumab for ≥12mo; 55% initiated ravulizumab within 2yrs of diagnosis. Any improvement in ≥1 HR-QoL measure was reported in 96% of patients; significant improvement in ≥1 HR-QoL measure was reported in 75% of patients. Most frequently reported improvements were in the ability to socialize/maintain relationships (73%), the ability to function in a career (71%), real or perceived social isolation (71%), the ability to complete ADLs (70%), and the ability to participate in hobbies, leisure, or volunteering (70%). Respondents reported satisfaction with infusion frequency (79%), symptom relief (78%), HR-QoL improvements (76%), and their overall treatment experience (77%). Primary drivers of satisfaction included HR-QoL improvements (50%) and Q8W infusion frequency (23%).
Conclusions:
These results demonstrate that the majority of survey respondents with gMG receiving ravulizumab in the US were overall satisfied with ravulizumab and experienced meaningful HR-QoL improvements.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.